Skip to main content

Advertisement

SpringerLink
Log in

Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib

  • Original paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

A clinical prognostic model derived from BR.21 trial was established by Florescu et al., which helped to identify a small group of patients with non-small cell lung cancer (NSCLC) who might be less likely to benefit from erlotinib therapy. Whether the prognostic model derived from Caucasian patients treated with erlotinib will be applied to Asian patients treated with gefitinib is still an open question. We reviewed a multi-center clinical trial of Chinese patients with NSCLC treated with gefitinib. The data were collected and analyzed according to the prognostic model reported by Florescu et al. One hundred and nineteen patients were included in the validation study. Twenty-eight patients, 61 patients, 27 patients, and 3 patients were classified into the Low Risk (LR) group, Intermediate Low Risk (ILR) group, Intermediate High Risk/High Risk (IHR/HR) group, respectively. The median overall survival of LR group was not reached, ILR and IHR/HR group was 8.9 months and 4.5 months, respectively. There was a significant difference in overall survival between LR group versus ILR group and IHR/HR group (P = 0.0003 and 0.0001, respectively). While IHR/HR group appeared to have less survival benefit than ILR group, the difference was not statistically significant (P = 0.148). The result has shown a similar effect as that seen by Florescu et al. in differentiating patient risk groups. Our study provides the potential evidence that the prognostic model might be applied to Asian patients with NSCLC treated with gefitinib and helps clinicians to select patients for gefitinib therapy and stratify patients within second-line clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. Cancer statistics, 2007. Cancer J Clin. 2007;57:43–66.

    Article  Google Scholar 

  2. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, et al. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007;2:845–53.

    Article  PubMed  Google Scholar 

  3. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–103.

    PubMed  CAS  Google Scholar 

  4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.

    Article  PubMed  CAS  Google Scholar 

  5. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer, ISEL study). Lancet. 2005;366:1527–37.

    Article  PubMed  CAS  Google Scholar 

  6. Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer. 2006;7:389–94.

    Article  PubMed  CAS  Google Scholar 

  7. Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K. SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs. 2006;17:401–9.

    Article  PubMed  CAS  Google Scholar 

  8. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, et al. Phase III study, V-15–32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008;26:4244–52.

    Article  PubMed  CAS  Google Scholar 

  9. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809–18.

    Article  PubMed  CAS  Google Scholar 

  10. Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA. National Cancer Institute of Canada Clinical Trials Group. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol. 2008;3:590–8.

    Article  PubMed  Google Scholar 

  11. Guan ZZ, Zhang L, Li LY, Jiang GL, Liu XY, et al. Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial. Ai Zheng. 2005;24:980–4. Article in Chinese.

    PubMed  Google Scholar 

  12. Park MJ, Lee J, Hong JY, Choi MK, Yi JH, et al. Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer. 2009;115:1518–30.

    Article  PubMed  CAS  Google Scholar 

  13. Satouchi M, Negoro S, Funada Y, Urata Y, Shimada T, et al. Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer. 2007;96:1191–6.

    Article  PubMed  CAS  Google Scholar 

  14. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493–501.

    Article  PubMed  CAS  Google Scholar 

  15. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–20.

    Article  PubMed  CAS  Google Scholar 

  16. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643–55.

    Article  PubMed  CAS  Google Scholar 

  17. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall- cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900–9.

    Article  PubMed  CAS  Google Scholar 

  18. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007;13:2890–6.

    Article  PubMed  CAS  Google Scholar 

  19. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009;361:947–57.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncology in Southern China & Department of Medical Oncology, Cancer Center, Sun Yat-sen University, 510060, Guangzhou, Guangdong Province, China

    Fenghua Wang, Yang Zhang, Hongyun Zhao, Likun Chen, Yan-Xia Shi & Li Zhang

Authors
  1. Fenghua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongyun Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Likun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan-Xia Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Zhang.

Additional information

Fenghua Wang, Yang Zhang authors contributed equally to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, F., Zhang, Y., Zhao, H. et al. Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib. Med Oncol 28, 331–335 (2011). https://doi.org/10.1007/s12032-010-9451-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9451-1

Keywords

Search

Navigation